To test this, we subcutaneously injected Flt3L at the dose of 800 μg/kg/day for 8 days in day-3 orthotopic HCC mice [26, 39, 40] and primed mice 7 days after tumor implantation with intravenous injection of DEXP&A&N (Fig. 6a). This evidence concerns the gene FLT3LG and hepatocellular carcinoma.